Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Gaurav Shah Biography and Net Worth

CEO of Rocket Pharmaceuticals

Gaurav Shah, a co-founder of Rocket Pharma, serves as Chief Executive Officer and Corporate Board Member. Prior to this role Gaurav was a Global Program Head in the Cell & Gene Therapies Unit at Novartis, where he had strategic oversight of 12 functions and helped spearhead pivotal trials with CART-19 for patients with leukemia and lymphoma. Earlier roles at Novartis included Global Clinical Program Head for CART-19 and for Biosimilars, and lead physician for Afinitor in several global oncology submissions. Gaurav started his career in industry at ImClone/Eli Lilly as a Medical Director overseeing oncology trials focused on monoclonal antibodies.

Gaurav graduated from Harvard College (summa cum laude, Phi Beta Kappa) with a degree in Behavioral Neuroscience. He received his MD from Columbia (AOA), completed his internal medicine residency at Brigham and Women’s Hospital, and hematology/oncology fellowship training at Memorial-Sloan Kettering. After receiving board certification in medical oncology, he served as an Adjunct Assistant Professor of Oncology at Columbia.

To find balance, Gaurav also has a passion for Indian classical music and has toured extensively including performances at Carnegie Hall and on National Geographic TV, a feature in the Smithsonian, and a 2019 Grammy nomination (Falu’s Bazaar).

What is Gaurav Shah's net worth?: The estimated net worth of Gaurav Shah is at least $8.18 million as of November 21st, 2024. Dr. Shah owns 707,328 shares of Rocket Pharmaceuticals stock worth more than $8,176,712 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Shah may own. Learn More about Gaurav Shah's net worth.
How do I contact Gaurav Shah?: The corporate mailing address for Dr. Shah and other Rocket Pharmaceuticals executives is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. Rocket Pharmaceuticals can also be reached via phone at (609) 659-8001 and via email at [email protected]. Learn More on Gaurav Shah's contact information.
Has Gaurav Shah been buying or selling shares of Rocket Pharmaceuticals?: In the last ninety days, Gaurav Shah has sold $144,737.55 of Rocket Pharmaceuticals stock. Most recently, Gaurav Shah sold 11,091 shares of the business's stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $13.05, for a transaction totalling $144,737.55. Following the completion of the sale, the chief executive officer now directly owns 707,328 shares of the company's stock, valued at $9,230,630.40. Learn More on Gaurav Shah's trading history.
Who are Rocket Pharmaceuticals' active insiders?: Rocket Pharmaceuticals' insider roster includes Gotham Makker (Director), John Militello (Insider), Jonathan Schwartz (Chief Gene Therapy Officer), and Gaurav Shah (CEO). Learn More on Rocket Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Rocket Pharmaceuticals?: During the last year, insiders at the biotechnology company sold shares 20 times. They sold a total of 444,818 shares worth more than $12,028,476.82. The most recent insider tranaction occured on November, 21st when insider John Militello sold 1,224 shares worth more than $15,973.20. Insiders at Rocket Pharmaceuticals own 28.5% of the company. Learn More about insider trades at Rocket Pharmaceuticals.
Information on this page was last updated on 11/21/2024.

Gaurav Shah Insider Trading History at Rocket Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/21/2024	Sell	11,091	$13.05	$144,737.55	707,328
5/16/2024	Sell	9,790	$23.35	$228,596.50	728,069
2/16/2024	Sell	20,272	$29.84	$604,916.48	554,762
8/17/2023	Sell	4,767	$15.47	$73,745.49	524,854
2/17/2023	Sell	12,194	$19.06	$232,417.64	536,885
2/7/2022	Buy	22,000	$17.34	$381,480.00
3/5/2019	Sell	74,900	$17.17	$1,286,033.00

Gaurav Shah Buying and Selling Activity at Rocket Pharmaceuticals

Rocket Pharmaceuticals Company Overview

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Today's Range

Now: $11.56

$11.15

$11.79

50 Day Range

MA: $15.11

$11.35

$18.82

2 Week Range

Now: $11.56

$11.15

$32.53

Volume

2,866,520 shs

Average Volume

843,288 shs

Market Capitalization

$1.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01